A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)
Status:
Recruiting
Trial end date:
2022-01-14
Target enrollment:
Participant gender:
Summary
The reason for this study is to assess the impact of lebrikizumab on vaccine immune response
in adult participants with moderate to severe atopic dermatitis (AD).